AKT1 and colitis: Our experiments demonstrated that low-dose IL-2 ameliorates DSS-induced intestinal tissue damage by restoring intestinal barrier integrity and exerting an inhibitory effect on the PI3K/AKT and NF-κB pathways in vivo, thereby protecting the intestinal epithelium against DSS-induced colitis.